Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYK2 | P29597 | 11/20 | 0.44 |
| ▸ | JAK2 | O60674 | 10/20 | 0.44 |
| ▸ | JAK1 | P23458 | 6/20 | 0.44 |
| ▸ | JAK3 | P52333 | 5/20 | 0.44 |
| ▸ | DHODH | Q02127 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28359015 | 1.00 | TYK2 (0.44) | TYK2JAK2JAK1JAK3DHODH | |
| SCHEMBL29922572 | 0.90 | JAK2 (0.46) | TYK2JAK2JAK1JAK3DHODH | |
| SCHEMBL28359248 | 0.90 | JAK2 (0.46) | TYK2JAK2JAK1JAK3DHODH | |
| SCHEMBL29552149 | 0.88 | TYK2 (0.46) | TYK2JAK2JAK1JAK3DHODH | |
| SCHEMBL29922588 | 0.85 | JAK2 (0.43) | TYK2JAK2JAK1JAK3DHODH | |
| SCHEMBL28359239 | 0.85 | JAK2 (0.43) | TYK2JAK2JAK1JAK3DHODH | |
| SCHEMBL29922647 | 0.85 | JAK2 (0.44) | TYK2JAK2JAK1JAK3DHODH | |
| SCHEMBL28358976 | 0.85 | JAK2 (0.44) | TYK2JAK2JAK1JAK3DHODH | |
| SCHEMBL28362639 | 0.85 | JAK2 (0.44) | TYK2JAK2JAK1JAK3DHODH | |
| SCHEMBL28362805 | 0.84 | JAK2 (0.44) | TYK2JAK2JAK1JAK3DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110818641-B | Pyridazine-3-formamide compound, preparation method and application thereof in medicine and pharmacology | 北京诺诚健华医药科技有限公司 | 2022-10-14 | — | — | CN | disclosed |